Substantial evidence: When is a single trial sufficient for approval and promotion

Drug Information Journal

Volumn 45, Issue 3, 2011, Pages 253-263

  Coutant, David ^a   Riggs, David ^a   Hoffman, Elizabeth Van Sant ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Clinical effectiveness; Promotion; Substantial evidence

Indexed keywords

EVEROLIMUS; PAZOPANIB; PLACEBO; TEMSIROLIMUS;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; RISK BENEFIT ANALYSIS; STANDARD; SUBSTANTIAL EVIDENCE;

EID: 80051807522     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286151104500306     Document Type: Article

References (24)

1. US FDA. Federal Food, Drug, and Cosmetic (FD&C) Act, chapter V: drugs and devices. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandC osmeticActFDCAct/FDCActChapterVDrugsandDevices/ucm108125.htm (accessed May 7, 2010).
2. US FDA. Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products. May 1998. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/UCM 078749.pdf (accessed May 7, 2010).
3. US FDA. Draft guidance for industry: integrated summary of effectiveness. August 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/UCM079803.pdf (accessed May 7, 2010).
4. US FDA. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. May 2007. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegula toryInformation/Guidances/UCM071590.pdf (accessed May 7, 2010).
5. Gould AL. Substantial evidence of effect. J Biopharm Stat. 2002;12:53-77.
6. US FDA. Taxotere (docetaxel) label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020449s044lbl.p df (accessed May 7, 2010).
7. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707-1714.
8. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2 (8607):349-360.
9. US FDA. Victoza (liraglutide) label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf (accessed May 7, 2010).
10. US FDA. Drugs @ FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/(accessed August 10, 2010).
11. Code of Federal Regulations. Title 21 Food and Drugs. Part 314.126. http://edocket.access.gpo.gov/cfr_2008/aprqtr/pdf/21cfr314.126.pdf (accessed May 7, 2010).
12. Temple RJ. NDA/demonstrating product effectiveness. Presentation at Unapproved Drugs Workshop, January 9, 1977. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapproved Drugs/ucm120000.pdf (accessed May 7, 2010).
13. ICH. ICH E9, statistical principles for clinical trials. http://www.ich.org/LOB/media/MEDIA485.pdf (accessed May 7, 2010).
14. US FDA. Draft guidance for industry: noninferiority clinical trials. March 2010. http://www.fda.gov/downloads/Drugs/GuidanceCom plianceRegulatoryInformation/Guidances/UCM202140.pdf (accessed August 11, 2010).
15. ICH. ICH E10, choice of control group and related issues in clinical trials. http://www.ich.org/LOB/media/MEDIA486.pdf (accessed May 7, 2010).
16. Powers JH. Increasing the efficiency of clinical trials of antimicrobials: the scientific basis of substantial evidence of effectiveness of drugs. Clin Trials Antimicrobials. 2007;45(Suppl 2):S153- S161.
17. MacMahon B, Yen S, Trichopoulos D, et al. Coffee and cancer of the pancreas. N Engl J Med. 1981; 304:630-633.
18. Temple R, Pledger G. The FDA's critique of the anturane reinfarction trial. N Engl J Med. 1980; 303:1488-1492.
19. Peck CC, Wechsler J. Report of a workshop on confirmatory evidence to support a single clinical trial as a basis for new drug approval. Drug Inf J. 2002;36:517-534.
20. Temple RJ. Examples of when protocol design became a critical factor in the success or failure of a product. Presentation to the Drug Information Association, June 21, 2006.
21. Temple RJ. FDA drug approval process, potential efficiencies and active control trials. Presentation to UNC School of Public Health, March 6, 2008.
22. Kessler DA. Expert report, July 31, 2008. http://www.pharmalot.com/wp-content/uploads/2008/10/neurontin-kessler.pd f (accessed May 7, 2010).
23. Code of Federal Regulations. Title 21 Food and Drugs. Part 202. http://edocket.access.gpo.gov/cfr_2008/aprqtr/pdf/21cfr202.1.pdf (accessed May 7, 2010).
24. US FDA. Warning letters and notice of violation letters to pharmaceutical companies. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Enforce mentActivitiesby FDA/WarningLettersandNoticeofViolationLet terstoPharmaceuticalCompanies/default.htm (accessed May 7, 2010).